352 Final Results of the First in Man Trial of MK4827, a Poly (ADP-ribose) Polymerase (PARP) Inhibitor with Antitumor Activity in BRCA Carriers and Sporadic Cancer Patients — Shahneen Sandhu (2012) | RDL Network
352 Final Results of the First in Man Trial of MK4827, a Poly (ADP-ribose) Polymerase (PARP) Inhibitor with Antitumor Activity in BRCA Carriers and Sporadic Cancer Patients
Shahneen Sandhu, William R. Schelman, George Wilding, Víctor Moreno, Richard D. Baird, Susana Miranda, Lucy Hylands, Ruth Riisnaes, Martin Förster, Aurelius Omlin, N. Kreischer, Khin Thway, Heidrun Gevensleben, Linda Sun, John W. Loughney, Manash Chatterjee, Carlo Toniatti, Christopher L. Carpenter, Robert Iannone, Stan B. Kaye, Johann S. de Bono, Robert M. Wenham
R.M. Wenham, Shahneen Sandhu, George Wilding, Linda Sun, Carlo Toniatti, Mark Stroh, Catherine L. Carpenter, Johann S. de Bono, Richard D. Baird, William R. Schelman
William R. Schelman, Shahneen Sandhu, Víctor Moreno, G. Wilding, Long Sun, Carlo Toniatti, Mark Stroh, N. Kreischer, Celia L. Carpenter, L. Rhoda Molife, S. B. Kaye, Johann S. de Bono, R.M. Wenham
Robert M. Wenham, George Wilding, Richard D. Baird, Linda Sun, Carlo Toniatti, Mark Stroh, Catherine L. Carpenter, Johann S. de Bono, Shahneen Sandhu, William R. Schelman
Discussion(0)
No comments yet. Be the first to comment.